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Background: Decision-analytic modelling (DAM) has become a widespread method in health technology assessments
(HTA), but the extent to which modelling is used differs among international HTA institutions. In Germany, the use of
DAM is optional within HTAs of the German Institute of Medical Documentation and Information (DIMDI). Our study
examines the use of DAM in DIMDI HTA reports and its effect on the quality of information provided for health policies.
Methods: A review of all DIMDI HTA reports (from 1998 to September 2012) incorporating an economic assessment
was performed. All included reports were divided into two groups: HTAs with DAM and HTAs without DAM. In both
groups, reports were categorized according to the quality of information provided for healthcare decision making.
Results: Of the sample of 107 DIMDI HTA reports, 17 (15.9%) used DAM for economic assessment. In the group
without DAM, conclusions were limited by the quality of economic information in 51.1% of the reports, whereas we
did not find limited conclusions in the group with DAM. Furthermore, 24 reports without DAM (26.7%) stated that
using DAM would likely improve the quality of information of the economic assessment.
Conclusion: The use of DAM techniques can improve the quality of HTAs in Germany. When, after a systematic review
of existing literature within a HTA, it is clear that DAM is likely to positively affect the quality of the economic
assessment DAM should be used.
Keywords: Health technology assessment; Health economic evaluation; Health economic modelling;
Cost-effectiveness; Cost-utility; Decision analysisBackground
In the process of health technology assessment, decision-
analytic modelling serves as an assessment approach for
economic evaluation. Performing economic evaluation in
the HTA has become a standard requirement of health-
care systems in many countries (e.g. the UK, Canada,
Australia), and DAM has been accepted as a valid analyt-
ical approach. The method is applied to synthesize existing
evidence on the costs and effectiveness of healthcare op-
tions and to determine an optimal strategy among them.
In recent years, the use of DAM for HTA has significantly
increased [1,2], and several studies providing good practice
guidelines for the use of DAM in HTA have been con-
ducted [2]. In particular, guidelines issued by HTA insti-
tutes in the UK and Canada provide detailed descriptions* Correspondence: ak@ivbl.uni-hannover.de
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In Germany, HTA was introduced in the 1990s. In 1995,
the German Federal Ministry of Health assembled a re-
search group and assigned it to review, assess and prepare
the implementation of data collection and to evaluate
medical procedures and technologies in Germany [3].
HTA was formally approved in Germany with the health-
care reform in 2000. The German Agency for Health
Technology Assessment (DAHTA) was established within
the German Institute of Medical Documentation and
Information (DIMDI). It was commissioned to implement
and operate a database, an information system and a
scientific working program on HTA [4,5]. The HTAs pub-
lished by DIMDI aim to primarily inform health policy and
not to provide recommendations for the benefits catalogue
of the Statutory Health Insurance (SHI) [5]. These HTA re-
ports include medical, economic, ethical, social and juridical
aspects [6]. Following the SHI Modernization Act in 2004,is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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tute for Quality and Efficiency in Health Care (IQWiG) was
established as an independent scientific body to perform
technology assessments on behalf of the Federal Joint Com-
mittee (G-BA; a supreme decision making body of the self-
governing healthcare system in Germany) or the Federal
Ministry of Health. The technology assessments serve to in-
form the decision making by the G-BA [5], and the reports
by IQWiG were limited to medical technology assessments.
Since 2007, with the German Act on reinforcing SHI compe-
tition, IQWiG may also be commissioned to perform cost-
benefit assessments.
The guidelines of both DIMDI and IQWiG indicate
that DAM may be necessary for economic assessment
of a technology [6,7]; however, the incorporation of a
model is not a requirement for developing an HTA for
publication by DIMDI, and DAM has become an op-
tional tool in practice. IQWiG sees modelling as essen-
tial for economic assessment and requires it in the
absence of comprehensive economic data [7]. Thus,
IQWiG has released detailed information on the
methods applied in modelling [8]. The DIMDI guide-
lines, which are summarized in its handbook, do not
provide specific methodological recommendations for
the development of DAM.
Considering the growing importance of performing sys-
tematic assessments of health technologies in Germany, it
is desirable to continue working on the development of
HTA methodologies, which may improve the quality of
HTA reports. One important direction may be to enhance
the application of decision models in German HTAs.
Therefore, in our study, we review the use of DAM in
German HTAs and analyse the effects of the use of DAM
on the quality of information provided for healthcare deci-
sion making. We also study decision models applied to
German settings and consolidate the main characteristics
of the models developed by the German HTAs. Because
IQWiG did not provide economic assessments by the time
of our analysis, we based our work on the HTA reports
published by DIMDI.Methods
Search strategy and exclusion criteria
Using the DAHTA database, we identified and extracted
all DIMDI HTA reports conducted during the period
from 1998 to September 2012. HTAs that did not
undertake economic assessments were excluded from
the analysis. The resulting sample of HTAs was divided
into two groups: HTAs that performed a systematic litera-
ture review and HTAs that developed a new decision-
analytic model (designed for the characteristics of the
German healthcare system) in addition to the literature
review for the economic assessment.Assessing the informativeness of HTA reports for decision
making
In order to analyse the informativeness of HTAs for de-
cision making, we developed an HTA classification based
on the quality of information provided in each HTA re-
port. We reviewed all included HTAs, focusing on the
following sections: the summary, the conclusion and the
answers provided to the research questions. Additionally,
we checked for consistency between these sections. We
defined three aggregate types that described the levels of
informativeness of the HTA report.
‘Conclusion’: The HTA provides a clear conclusion
regarding the medical effectiveness or cost-effectiveness
of the health technology (technologies) under assess-
ment. Uncertainty is low and further research is unlikely
to affect the given conclusion.
‘Limited conclusion’: Authors on an HTA formulate a
general suggestion regarding the medical effectiveness/cost-
effectiveness of the health technology (technologies) under
assessment, but the conclusion is limited because of the
limitations of the reviewed evidence. Major limitations of
the study are explained through either the low quality of
the reviewed studies or the difficulties of applying the exist-
ing evidence to the German health care system. The latter
generally occurs when conducting an economic assessment
because of the differences in the healthcare structures and/
or resource prices. In addition, the uncertainty is significant,
and further research is likely to have a considerable effect
on the results and may change the provided inferences.
‘No conclusion’: Authors of an HTA cannot provide an
assessment of medical effectiveness and cost-effectiveness
of the health technology (technologies) because of the lack
of scientific evidence in the reviewed literature.
Assessing the impact of decision-analytic modelling on
the informativeness of HTA reports
The medical effectiveness of interventions is a key input
parameter in decision-analytic models. The evidence of
medical effectiveness affects the quality of information pro-
vided in health economic evaluations. Low-quality medical
evidence can be a barrier for conducting economic ana-
lysis. Consequently, the existing medical evidence has to be
taken into account when assessing the impact of decision-
analytic modelling on the informativeness of HTA reports.
Therefore, we reviewed the medical part and the economic
part of each HTA separately. Using the three types of in-
formativeness, six categories (CAT I-VI) were formed to
classify the HTA reports. Table 1 shortly sketches these
categories. The first row and column of the table provide
the level of information related to the medical and eco-
nomic assessments, respectively. Combinations between
the type of the medical part and the type the economic
part constitute the six categories shown in the intersection
cells of the table.
Table 1 Categorization of HTA conclusions based on the
‘quality level’ of information for decision making
Economic assessment
Conclusion Limited
conclusion
No
conclusion
Medical
assessment
Conclusion I II III
Limited
conclusion
not applicable IV V
No conclusion not applicable not applicable VI
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quality of information given in the economic portions
of the HTAs, we compared medical and economic as-
sessments of each report in the sample and analysed the
difference between their levels of informativeness. HTA re-
ports in CAT VI were excluded from the analysis, since the
reports in this category provide insufficient medical evi-
dence for progressing to economic evaluation. For each of
the groups, ‘HTA with a model’ and ‘HTA without a model’,
we determined the percentage of HTAs in which the eco-
nomic assessment provides significantly lower quality of in-
formation than the medical assessment (CATs II, III and
V). We compared “with-” and “without a model” groups
based on these percentages to reduce potential bias, in case
both groups are not comparable with respect to the re-
ported level of information in the medical assessment.
The review and the classification of the reports were
undertaken by two researchers independently, and any
distinctions were discussed and clarified. The HTA re-
ports with new model development were further ana-
lysed with respect to the applied modelling methods.
The aim of the further analyses was to characterize and
compare the techniques used that focused on the se-
lected key components of modelling: the economic
evaluation type, the model type, the time horizon, the
perspective, the primary medical outcome, the dis-
count factor and the type of sensitivity analyses. These
components were extracted according to the individual
descriptions provided in the HTA reports.
Results
Sample size
In the period from 1998 to September 2012, 158 DIMDI–
HTA reports were conducted, published and indexed in the
DAHTA database. Of these, 20 methodological reports
were excluded during the screening process. Another 31 re-
ports did not meet the inclusion criterion of an economic
assessment of the health technology. The resulting sample
of 107 HTA reports was divided into reports that include
the development of a new model for the German health-
care system and those that only performed a systematic lit-
erature review for economic assessment. In total, 17 HTA
reports (approximately 16%) developed such a model,whereas the other 90 reports did not. Figure 1 summarizes
the selection procedure (A list of all identified reports is
presented in the Additional file 1: Table S2 to Table S5).
Informativeness of DAHTA reports
The medical and economic parts of the 107 HTAs in our
sample are grouped into the three aggregate types. Of our
sample, 29 reports (27.1%) state a clear conclusion regard-
ing the medical effectiveness of a technology in the assess-
ment, and 15 reports (14%) provide a conclusion regarding
cost-effectiveness in the economic section. Another 44 re-
ports (41.1%) state a general suggestion on medical effect-
iveness. The conclusion on cost-effectiveness is significantly
limited in 36 reports (33.6%). In 34 reports (31.8%), it is
not possible to conduct a medical assessment because of
the lack of scientific evidence in the reviewed literature.
An economic conclusion could not be drawn in 56 reports
(52.3%), either because of the lack of economic evidence
or because the results of the international studies are not
applicable to the German setting. Figure 2 shows the re-
sults of the division of the reports into the types for the
groups of ‘HTAs with a model’ and ‘HTAs without a
model’. In the sample of HTAs with a model, a higher per-
centage of reports provide information for decision mak-
ing in the medical assessment compared to the sample of
HTAs without a model (conclusion is given in 52.9% vs.
22.2%; conclusion is limited in 41.2% vs. 41.1%). Of the re-
ports that applied DAM, 94.1% provide either a clear con-
clusion (32.2%) or a limited conclusion (61.1%) on the
cost-effectiveness of the technology/technologies under
assessment compared with 38.9% in the group without a
model (conclusion: 6.7%; limited conclusion: 32.2%).
Overall, the proportion of HTA reports that provide infor-
mation on the assessed health technology for decision mak-
ing (CAT I–V) is 68.2% (73 out of 107 reports), of which 15
reports draw a clear conclusion on both the medical and
economic assessments (CAT I). Another 14 reports either
draw a clear conclusion on effectiveness but provide only a
general suggestion on cost-effectiveness (CAT II; seven re-
ports), or they are not able to provide a conclusion on cost-
effectiveness based on the reviewed evidence (CAT III; seven
reports). Of the 44 reports that provide a general suggestion
on medical effectiveness, 29 reports also provide a general
suggestion on cost-effectiveness (CAT IV) and 15 are not
able to assess the cost-effectiveness because of a lack of evi-
dence (CAT V). In addition, 31.8% (34 of 107 reports) of the
reports are grouped in CAT VI, because they cannot draw a
conclusion on medical effectiveness or cost-effectiveness.
Among the 90 HTAs without a new model 57 (63.3%) give
information for decision making (CAT I–V). The majority of
these (51 reports) provide only a general opinion on the
medical effectiveness or cost-effectiveness of the health tech-
nology (technologies) under assessment (CAT II–V); thus,
further research is likely to have an important effect and may
Figure 1 Selection process for report inclusion. *As of September 2012.
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II, III, IV and V are 7, 7, 22 and 15, respectively.
The HTA reports with a developed model provide in-
formation for decision making (CAT I–V) in 16 out of
the 17 cases (94.1%). Of these, nine HTAs draw a clear
conclusion and provide high-quality information in both
the medical and economic assessment (CAT I), and
seven HTAs provide a general suggestion on both effect-
iveness and cost-effectiveness (CAT IV).
Impact of decision-analytic modelling on informativeness
of DAHTA reports
Of the HTA reports that did not develop a decision-
analytic model for the German healthcare system, 51.1%
provide significantly less information in the economic as-
sessment compared with the medical assessment. Of the
20 reports that provide a conclusion in the medical assess-
ment, 7 provide suggestions in the economic assessment
and another 7 cannot draw a conclusion. Of the 37 reports
with a limited conclusion on effectiveness in the medical
assessment, 15 reports provide no information on cost-
effectiveness in the economic assessment. In the group of
HTAs that apply DAM techniques, no report provides sig-
nificantly less information in the economic assessment
compared with the medical assessment. Figure 3 illustrates
the results for both groups.
Additionally, we reviewed the proportion of HTAs that
reported a requirement for further economic research. The
majority of these reports (86 of 107) conclude that add-
itional economic evidence is required in the literature. Of
the 90 reports that conduct only an economic systematic
literature research, 26.7% (24 reports) state that thedevelopment of a model is likely to improve the quality of
information of the economic assessment. Six of the HTAs
that used DAM provide recommendations to update the
models as soon as new medical evidence is available.
Economic evaluations for the German settings are re-
trieved in 36 of 107 HTA reports; however, none of
these evaluations significantly affected the level of infor-
mation in the economic assessments, mainly because of
either the low quality of the evaluation or the use of out-
dated economic or medical data.
Characteristics of decision-analytic models
Seventeen of the HTA reports in our sample developed
new decision-analytic models for the German settings.
Here, we provide a review of these and focus on the se-
lected key components of health economic modelling.
Table 1 in the supplements summarizes the results. One
model was not completed because of the lack of medical
evidence of important input parameters, and this model
is excluded from the following review.
Type of economic evaluation
Overall, 10 cost-effectiveness analyses and 2 cost-utility
analyses were conducted within the 16 HTAs. Three
HTA reports include examination of costs, and one re-
port includes both a cost-effectiveness analysis and a
cost-utility analysis.
Model type
The applied DAM techniques are identified in 63% (10
of 16) of the HTAs. In six HTAs, economic evaluations
are based on Markov models. Three HTA reports apply
Figure 2 Results of the division of HTA reports into the types.
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sion tree and the Markov model. Another report pre-
sents a Markov chain Monte Carlo simulation in which,
in contrast with common cohort modelling, virtual pa-
tients are simulated on an individual level with the im-
plication of a stochastic process (i.e. a micro-simulation).
The remaining six HTAs calculate results on the basis of
simple calculations.
Discount factor
Overall, 11 of the 16 models apply a discount rate in the
economic evaluations. Of these, six models use a 3% an-
nual discount rate and five models use a 5% discount rate
for both health effects and costs. In one model, it is un-
necessary to discount because the economic evaluation is
performed for a short time horizon (1 year). One model
omits discounting of the costs and benefits, albeit it per-
forms the economic evaluation for a time horizon of
3 years. The other three models report no discount rate.Perspective
Of the 16 reviewed models, four state a social perspec-
tive. Three models describe the perspective as a nar-
rowed social perspective. The perspective of two models
is that of the German statutory health insurance. One
model uses the scope of a healthcare provider and in-
cludes additional costs in its evaluation. Five models
state no perspective; however, the outcomes of the
models probably reflect the perspective of the statutory
health insurance. One model uses the perspective of the
German healthcare system.Primary medical outcome
Three models use life years to value health outcomes and
two models use QALYs. One model bases the economic
evaluation on both life years and QALYs. The rest of the
models calculate health outcomes specific to the character
of the disease or the technology under assessment.
Figure 3 Impact of decision-analytic modelling on the conclusion of HTA reports.
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All 16 models conduct sensitivity analyses. All models
apply a one-way sensitivity analysis; in addition, three re-
ports also perform a multi-way analysis and two perform
a probabilistic sensitivity analysis.Discussion
Following the objective of this work, we searched for evi-
dence that developing a new decision-analytical model im-
proves the quality of information of HTAs for decision
making in the German healthcare sector.
Therefore, we reviewed all HTAs published from DIMDI
that included economic assessments and classified them
according to the quality level of the information provided
for decision making. The results of this study suggest
that HTAs perform better when they build a new deci-
sion model for economic evaluation. Particularly, the
review showed that all HTAs with developed models
were capable of providing economic evidence for deci-
sion making with the quality of the information at least
equivalent to that provided by the medical portion. In
contrast, over 50% of HTA reports without model gave
a lower level of information in the economic assess-
ments than in the medical assessment. Moreover, ap-
proximately 80% of the reviewed HTAs concluded that
there is a need for further economic research, and 27%
(24 reports) of the HTAs without a model stated that
the development of a decision-analytic model might im-
prove the quality of the information of the economic as-
sessment. These findings indicate that using DAM in
DAHTA reports is not related to the need for additional
economic information.In our analysis, we also found differences between the
models in their quality and complexity. The review of
HTAs with models indicated that cost-effectiveness ana-
lysis with Markov models was the preferred type of eco-
nomic evaluation. Although the majority of the selected
HTAs with models incorporated the key elements of mod-
elling, some differences in the applied methods were ob-
served. These differences occurred in valuing medical
outcomes, the stated perspectives and the applied annual
discount rate. Not all the applied methods were up-to-
date. For example, for addressing uncertainty, a one-way
sensitivity analysis but no probabilistic sensitivity analysis
was mostly conducted.
Current shortcomings of the HTA reports and the
differences between the applied methods might com-
plicate decision making processes and might decrease
the role of HTAs as sources of information in health-
care. Elaboration of official standards and recommen-
dations on the use of decision-analytic models in HTA
might solve the discrepancies in the applied methods.
Imposing a requirement of justifying and clarifying the
necessity for modelling seems to be useful. Thus, re-
quiring DAM is necessary when, after conducting a
systematic literature review, it is justified that a model
would improve the results of assessment in terms of
informing decision making.
The current description of the HTA methods by DIMDI
lacks guidance on both, methods for conducting decision
modelling and for assessment of cost-effectiveness (e.g.
ICER vs. the Efficiency Frontier of the IQWiG [7]). Since
these aspects are interconnected, they are both essential
for the production of consistent results among HTAs.
For instance, if the assessment of cost-effectiveness
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generic measure such as QALY should be applied in
modelling. When developing a guide on decision mod-
elling in HTA, both the modelling methods and the as-
sessment of outcomes must be considered. Additionally,
it is desirable to consider the requirements and needs of
the users of HTA reports. For instance, requests by deci-
sion makers may determine the applied perspective (e.g.
societal or sickness funds).
Some limitations of this study should be considered
when contemplating the results. First, because of the di-
versity and complexity of the HTAs conclusions pro-
vided, the types and categories of our classifications are
broadly defined. A more precise grouping might change
the results of the classifications, but it would unlikely
affect the overall conclusion of our study. Second, the
classifications were performed based on the concluding
statements provided by the authors of the HTAs; there-
fore, we did not conduct an assessment of the evidence
reviewed in the reports. Among the HTA researchers,
distinctions in valuing the existing evidence may exist.
These differences might in turn bias our work.
Despite the limitations, this study provides new infor-
mation on conducting HTA in Germany regarding the
use of DAM. It also indicates the lack of economic re-
search in the German HTAs as well as the need for in-
creased and improved economic evaluations conducted
for HTAs.
Conclusion
Our review shows that it is necessary to improve eco-
nomic evaluations for HTAs produced in Germany. The
results of the analysis suggest that the use of modelling
improves the quality of economic assessment and
thereby the overall performance of an HTA, however,
the number of HTAs that conduct modelling is small.
In order to enhance the quality of HTAs in Germany, it
is desirable to develop a procedure for incorporating
decision-analytic models in the economic assessments
of reports. As long as the application of modelling is
not necessary for every HTA study, it seems reasonable
to develop a model on request after a systematic literature
review clarifies that DAM is likely to have a positive im-
pact on the economic assessment quality. In order to
guarantee good modelling quality and consistency of
the applied methods, designing and expanding the good
practices guide for the use of DAM for DIMDI–HTAs
is required.
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